IVX Stock Overview
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Invion Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.009 |
| 52 Week High | AU$0.019 |
| 52 Week Low | AU$0.008 |
| Beta | 1.1 |
| 1 Month Change | 0% |
| 3 Month Change | -10.00% |
| 1 Year Change | -50.00% |
| 3 Year Change | -25.00% |
| 5 Year Change | -40.00% |
| Change since IPO | -97.72% |
Recent News & Updates
Recent updates
Is Invion (ASX:IVX) In A Good Position To Invest In Growth?
Dec 08
We're Not Very Worried About Invion's (ASX:IVX) Cash Burn Rate
Aug 16A Look At The Fair Value Of Invion Limited (ASX:IVX)
Nov 04Estimating The Intrinsic Value Of Invion Limited (ASX:IVX)
Mar 23We Think Invion (ASX:IVX) Can Easily Afford To Drive Business Growth
Nov 26
Shareholder Returns
| IVX | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | -4.4% | 0.6% |
| 1Y | -50.0% | -25.2% | 3.5% |
Return vs Industry: IVX underperformed the Australian Pharmaceuticals industry which returned -25.2% over the past year.
Return vs Market: IVX underperformed the Australian Market which returned 3.5% over the past year.
Price Volatility
| IVX volatility | |
|---|---|
| IVX Average Weekly Movement | 12.3% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: IVX is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: IVX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Thian Chew | https://www.inviongroup.com |
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.
Invion Limited Fundamentals Summary
| IVX fundamental statistics | |
|---|---|
| Market Cap | AU$57.78m |
| Earnings (TTM) | -AU$2.24m |
| Revenue (TTM) | AU$3.29m |
17.6x
P/S Ratio-25.8x
P/E RatioIs IVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVX income statement (TTM) | |
|---|---|
| Revenue | AU$3.29m |
| Cost of Revenue | AU$2.32m |
| Gross Profit | AU$969.12k |
| Other Expenses | AU$3.21m |
| Earnings | -AU$2.24m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00035 |
| Gross Margin | 29.44% |
| Net Profit Margin | -68.09% |
| Debt/Equity Ratio | 0% |
How did IVX perform over the long term?
See historical performance and comparison